The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 09, 2019

Filed:

Aug. 03, 2015
Applicant:

Engmab Ag, Pfäffikon, CH;

Inventors:

Minh Diem Vu, Wollerau, CH;

Klaus Strein, Weinheim, DE;

Oliver Ast, Bassersdorf, CH;

Marina Bacac, Zurich, CH;

Lydia Jasmin Hanisch, Birmensdorf, CH;

Tanja Fauti, Zurich, CH;

Anne Freimoser-Grundschober, Zurich, CH;

Ralf Hosse, Cham, CH;

Christian Klein, Bonstetten, CH;

Ekkehard Moessner, Kreuzlingen, CH;

Samuel Moser, Rotkreuz, CH;

Ramona Murr, Zurich, CH;

Pablo Umana, Wollerau, CH;

Sabine Jung-Imhof, Planegg, DE;

Stefan Klostermann, Neuried, DE;

Michael Molhoj, Munich, DE;

Joerg Regula, Munich, DE;

Wolfgang Schaefer, Mannheim, DE;

Assignee:

ENGMAB AG, Wilen, CH;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/00 (2006.01); C07K 16/28 (2006.01); C07K 16/46 (2006.01); C07K 16/30 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2878 (2013.01); C07K 16/2809 (2013.01); C07K 16/3061 (2013.01); C07K 16/468 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/35 (2013.01); C07K 2317/522 (2013.01); C07K 2317/526 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/64 (2013.01); C07K 2317/66 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01);
Abstract

A bispecific bi- or trivalent antibody specifically binding to the two targets which are extracellular domain of human B cell maturation antigen (BCMA) and human CD3ε, wherein the variable domains VL and VH in a light chain and the respective heavy chain are replaced by each other, characterized in comprising a constant domain CL wherein the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat), and in the respective constant domain CH1 the amino acid at position 147 and the amino acid at position 213 is substituted independently by glutamic acid (E), or aspartic acid (D) (numbering according to EU index of Kabat). Also the manufacture and use of said antibody.


Find Patent Forward Citations

Loading…